Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Multiple Myeloma 121Neoplasms, Plasma Cell 36Neoplasms 14Carcinoma, Hepatocellular 13Recurrence 12Brain Neoplasms 12Prostatic Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Glioblastoma 10Leukemia 9Carcinoma, Non-Small-Cell Lung 9Leukemia, Lymphocytic, Chronic, B-Cell 8Gliosarcoma 8Waldenstrom Macroglobulinemia 7Sarcoma 7Lung Neoplasms 7Glioma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Liver Neoplasms 6Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Kidney Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, Follicular 4

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Uterine Corpus Sarcoma × Thalidomide × Clear all
NCT00025220 2019-07-23

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡